GPR120 Agonist 2
Based on 1 Customer Validation
GPR120 Agonist 2 (example 206) is a GPR120 agonist that can be uesd for the study of type II diabetes and diseases associated with poor glycemic control.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.07%
- CAS No.: 1234844-11-1
- Formule: C22H25ClO4
- Masse moléculaire:388.88
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-19995
GSK137647AFFA4 Agonist -
HY-100881
TUG-891FFA4/GPR120 Agonist -
HY-50162
GPR120 modulator 1GPR120 Modulator -
HY-50691
GW-1100Free Fatty Acid Receptor Antagonist -
HY-101492
GPR120 Agonist 3GPR120 Agonist -
HY-50172
GPR120 modulator 2GPR120 Modulator -
HY-13967B
AMG 837 calcium hydrateGPR40/FFA1 Agonist -
HY-B1021
VincamineVasodilator -
HY-N0040
Ginsenoside Rb2Influenza Virus Inhibitor -
HY-111763
GPR40/FFAR1 modulator 1Free Fatty Acid Receptor Agonist -
HY-15697
TUG-770GPR40/FFA1 Agonist -
HY-100775
Fezagepras sodiumGPR40/GPR84 Modulator
Activité biologique
Description
IC50 & Target
GPR120[1]
In Vitro
GPR120 Agonist 2 is a GPR120 agonist which is useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1234844-11-1
-
Appearance Solid
-
Masse moléculaire 388.88
-
Formule C22H25ClO4
-
Color White to off-white
-
SMILES
O=C(O)CCC1=CC=C(OCC2=C(OC(C)(C)C3)C3=CC(Cl)=C2)C(C)=C1C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
In Vitro:
DMSO : ≥ 50 mg/mL (128.57 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.5 mg/mL (9.00 mM); Clear solution
This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5715 mL | 12.8574 mL | 25.7149 mL | 64.2872 mL |
| 5 mM | 0.5143 mL | 2.5715 mL | 5.1430 mL | 12.8574 mL | |
| 10 mM | 0.2571 mL | 1.2857 mL | 2.5715 mL | 6.4287 mL | |
| 15 mM | 0.1714 mL | 0.8572 mL | 1.7143 mL | 4.2858 mL | |
| 20 mM | 0.1286 mL | 0.6429 mL | 1.2857 mL | 3.2144 mL | |
| 25 mM | 0.1029 mL | 0.5143 mL | 1.0286 mL | 2.5715 mL | |
| 30 mM | 0.0857 mL | 0.4286 mL | 0.8572 mL | 2.1429 mL | |
| 40 mM | 0.0643 mL | 0.3214 mL | 0.6429 mL | 1.6072 mL | |
| 50 mM | 0.0514 mL | 0.2571 mL | 0.5143 mL | 1.2857 mL | |
| 60 mM | 0.0429 mL | 0.2143 mL | 0.4286 mL | 1.0715 mL | |
| 80 mM | 0.0321 mL | 0.1607 mL | 0.3214 mL | 0.8036 mL | |
| 100 mM | 0.0257 mL | 0.1286 mL | 0.2571 mL | 0.6429 mL |
GPR120 Agonist 2 Related Classifications
HY-111353 Related Classifications
Powered by Bioz